ArticleTransboundary and emerging diseases2026
Inhibitory Effects of Enoxolone on Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhibitory Effects of Enoxolone on Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Porcine epidemic diarrhea (PED) is characterized as an acute and highly contagious intestinal ailment induced by the PED virus (PEDV), presenting clinical symptoms such as emesis, diarrhea, and dehydration. The occurrence of PED has imposed a substantial economic burden on the global swine farming industry. The PEDV strain exhibits a proclivity for mutations, and the immune response elicited by traditional vaccines may prove ineffective against the virus. Meanwhile, given concerns about the tolerance to existing drugs. Consequently, there is an urgent necessity to develop novel anti PEDV drugs. As a natural compound, studies have demonstrated that enoxolone possesses multiple pharmacological attributes, encompassing antitumor, antiulcer, antiviral, and anti-inflammatory activities both in vivo and in vitro. In this study, we investigated the antiviral efficacy of enoxolone against PEDV. Enoxolone inhibits the proliferation of PEDV through multiple pathways. Initially, it degrades the nucleocapsid (N) protein via the lysosomal-autophagy pathway. Additionally, in vitro experiments have demonstrated that Enoxolone suppresses the NF-κB signaling pathway activated by PEDV, indicating its anti-inflammatory properties and its ability to inhibit the inflammatory response triggered by PEDV in vitro. Furthermore, in vivo results show that enoxolone effectively alleviates the symptoms and intestinal damage caused by PEDV in piglets. Briefly speaking, our research verifies that enoxolone can inhibit the replication of PEDV both in vivo and in vitro, providing a novel direction for the development of antiviral drugs against PED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.